the life science kpi's were a total bust. after that presentation eugeni was scraped, Charlie moved on and the company had to launch a new product anteobindNXT, with a new costing structure. it's a wait and see but with all the papers you have posted on h/c, our tech still has potential for commercialisation
the CET kpi's weren't so bad IMO. as per usual with ado the wyon and trinseo mou's have faded away without comment. I can understand trinseo with its <30% silicon anode exclusivity clause and their relationship with ferro not moving forward. Wyon ??? speaking of ferro, management has to be given some slack with negotiation with the patent court case hanging over us for 8 months of that period.
and while we are comparing. compare the update in Feb 23 to the one released last week and the progress the company has made. Hmmmm !!!! add these as well
- technical transfer to 3rd party to manufacturer ev1's full anode + our 70% silicon anode
- production facility completed with max capacity expanded to 1000k litres
- cost saving data of using anteoX for ev1 of US$500
- reaching 1000 cycles with ev1 at 72% retention
- expansion of partnerships with major ev, consumer electronics, giga factories and battery manufacturers
- expansion on potential income into nano tubes, separators and large battery storage
- progression to ev1's protype
- collection of CET technical data
- international sale recruitment to service European and US customers
not holding my breath either. I've talked to a few shareholders over time, that were all of the same opinion that no CET company would sign a commercial deal with the ferro court case hanging over our head, not being able to confirm that we can manufacture at scale and having a full battery reach 1000 cycles. all pretty much completed a couple of months ago (even though confirmation hasn't been given officially about our prod facility).
the next few months will be pivotal. GLTAH
ADO Price at posting:
2.2¢ Sentiment: Buy Disclosure: Held
